Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Falcone

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Leukemia & Lymphoma|July 7, 2023
Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese"Giuseppe Mele, Nicola Di Renzo, Nicola Cascavilla, et al.
Leukemia|July 17, 2014
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survivalS Ferrero, M Ladetto, D Drandi, et al.
Blood|September 3, 2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patientsSara Bringhen, Alessandra Larocca, Davide Rossi, et al.
Leukemia|December 24, 2016
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysisF Gay, S Oliva, M T Petrucci, et al.
Annali Di Igiene : Medicina Preventiva E Di Comunita|April 20, 2022
The management of endoscopic retrograde cholangio- pancreatography-related infections risk: results of an italian survey at regional levelV Cennamo, S Landi, G Aragona, et al.
Leukemia|February 23, 2016
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myelomaA Larocca, S Bringhen, M T Petrucci, et al.
Hemasphere|January 24, 2025
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL studySonia Morè, Irene Federici, Alessandra Bossi, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Leukemia & Lymphoma|July 7, 2023
Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese"Giuseppe Mele, Nicola Di Renzo, Nicola Cascavilla, et al.
Leukemia|July 17, 2014
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survivalS Ferrero, M Ladetto, D Drandi, et al.
Blood|September 3, 2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patientsSara Bringhen, Alessandra Larocca, Davide Rossi, et al.
Leukemia|December 24, 2016
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysisF Gay, S Oliva, M T Petrucci, et al.
Annali Di Igiene : Medicina Preventiva E Di Comunita|April 20, 2022
The management of endoscopic retrograde cholangio- pancreatography-related infections risk: results of an italian survey at regional levelV Cennamo, S Landi, G Aragona, et al.
Leukemia|February 23, 2016
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myelomaA Larocca, S Bringhen, M T Petrucci, et al.
Hemasphere|January 24, 2025
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL studySonia Morè, Irene Federici, Alessandra Bossi, et al.
Pageof 2